At the ASRS meeting, Dr. Michael A. Singer discussed the topline results of the phase 2b/3 RESTORE study on MCO-010 for treating retinitis pigmentosa. The study investigated two doses of optogenetic therapy compared to sham, focusing on changes in vision over 52 weeks as the primary endpoint. Results showed significant improvement in vision with no serious adverse events, indicating meaningful visual improvement in legally blind individuals with retinal degeneration. The study demonstrated durable visual improvement at 2 years, suggesting a promising treatment option for those with progressive and permanent neurodegeneration of the retina.
Source link
MCO-010 for retinitis pigmentosa improves vision in phase 2b/3 study
